ReachBio Research Labs
- Company typePrivate
- Founded2007
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ReachBio Research Labs does
The company operates a specialty life-sciences tools and services platform centered on in vitro preclinical testing systems that replicate in vivo environments for drug development research. Its core offering is organized under the Gentest® brand and spans two integrated lines: (1) branded reagent products — primary human hepatocytes (Gentest® Hepatocytes), recombinant enzymes (Supersomes®), cell-based transporter assays (TransportoCells™), and human liver microsomes — for in vitro ADME-Tox testing; and (2) ADME research services covering enzyme induction, enzyme inhibition, reaction phenotyping, and transporter interaction studies designed to support IND-enabling submissions. The portfolio is positioned as regulatory-guideline-aligned and is sold to biopharma companies (primary), cell & gene therapy developers, clinical diagnostics firms, and government, nonprofit, and academic research institutions.
ReachBio Research Labs firmographics
Firmographics- Name
- ReachBio Research Labs
- Website
- https://reachbio.com
- Company type
- Private
- Founded year
- 2007
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ReachBio Research Labs industry classification
Industry- Product category
- Preclinical ADME-Tox Reagents and Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- DMPK / ADME & Bioanalysis (HLAGAFAC)
- akta.pro secondary industry
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)
Keywords
Where ReachBio Research Labs is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
ReachBio Research Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Preclinical ADME-Tox Products: Sale of in vitro preclinical products including hepatocytes, Supersomes, TransportoCells, and human liver microsomes for drug metabolism and toxicity testing
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
ReachBio Research Labs product offering
Product offeringCore offering
ReachBio Research Labs provides a portfolio of in vitro preclinical ADME-Tox products and IND-enabling services for drug development. The product line includes primary human hepatocytes, Supersomes® recombinant enzymes, TransportoCells™ transporter cells, and human liver microsomes, while the service line covers enzyme induction, enzyme inhibition, reaction phenotyping, and transporter interaction studies. Together, the products and services form an integrated ADME and toxicology solution that uses in vitro systems to closely replicate in vivo drug behavior.
Product overview
Discovery Life Sciences (via its Gentest® brand) offers a comprehensive portfolio of in vitro preclinical products and services for drug development. The offering consists of two main categories: (1) Products including Hepatocytes, Supersomes®, TransportoCells™, and Human Liver Microsomes for in vitro ADME-Tox testing; and (2) Services including Enzyme Induction, Enzyme Inhibition, Reaction Phenotyping, and Transporter Interaction studies. Together, these products and services form an integrated IND-enabling ADME and toxicology solution designed to help researchers answer drug development questions using in vitro systems that closely replicate the in vivo environment.
Differentiator
Problem solved
Functional benefit
Companies that use ReachBio Research Labs
Customer profileSegments4 records
Ideal customer profiles4 records
ReachBio Research Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ReachBio Research Labs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BiocartiscoreDiscovery Life Sciences and Biocartis announced a strategic collaboration to advance precision oncology diagnostics, providing rapid molecular testing capabilities in the U.S. and EU markets.
Scale indicators1 record
Expansion highlights4 records
ReachBio Research Labs competitors and assessment
Company assessmentBroad incumbents
- Eurofins Discovery: Offers ADME-Tox, DMPK, and broader preclinical discovery services within the Eurofins network. Competes in the same biopharma buyer workflow as Gentest® for outsourced IND-enabling studies.
- Lonza: Manufactures primary hepatocytes and cell-based assay platforms and offers preclinical ADME services. Overlaps with Gentest® products (hepatocytes, cell-based systems) while also serving as a broader cell-and-gene-therapy CDMO.
- Corning Life Sciences: Major life-science supplier with a portfolio of primary hepatocytes (HepatoCells), transwells, and cell-based assay systems. Competes across the Gentest® product line as part of a much broader catalog and larger commercial footprint.
- Thermo Fisher Scientific: Global life-science incumbent offering Gibco hepatocytes, microsomes, and outsourced ADME-Tox services through its PPD clinical research business. Competes across both the reagent and service layers with substantial pricing and bundling power.
- Charles River Laboratories: Large preclinical CRO with extensive ADME-Tox and DMPK service capabilities. Competes with Gentest® ADME Services for IND-enabling studies, particularly for biopharma sponsors seeking integrated discovery-to-IND packages.
Direct peers
- Cyprotex (Evotec): Dedicated ADME-Tox and DMPK preclinical services provider (now part of Evotec). Competes directly with the Gentest® ADME Services portfolio for IND-enabling studies such as enzyme induction, inhibition, and reaction phenotyping.
- Sekisui Xenotech: Specialized provider of in vitro ADME-Tox products and services including hepatocytes, subcellular fractions, and enzyme induction/inhibition assays. Closest direct competitor to the Gentest® portfolio across both reagents and IND-enabling services.
- BioIVT: Supplies human and animal biospecimens plus ADME-Tox reagents and services to biopharma. Direct competitor in primary hepatocytes and in vitro preclinical products with overlapping biopharma customer base.
Emerging players
- Pharmaron: Integrated CRO offering in vitro and in vivo ADME-Tox services alongside discovery and manufacturing. Increasingly competes for biopharma IND-enabling work that overlaps with Gentest® ADME Services.
- Inotiv: Preclinical research services provider with ADME/PK and safety assessment capabilities, particularly for early-stage and specialty biopharma sponsors. Partially overlaps with the Gentest® ADME Services offering at smaller scale.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
ReachBio Research Labs social profiles
Digital presenceReachBio Research Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
ReachBio Research Labs leadership team
Management profileNumber of profiles
ReachBio Research Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ReachBio Research Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ReachBio Research Labs
What does ReachBio Research Labs do?
ReachBio Research Labs provides a portfolio of in vitro preclinical ADME-Tox products and IND-enabling services for drug development. The product line includes primary human hepatocytes, Supersomes® recombinant enzymes, TransportoCells™ transporter cells, and human liver microsomes, while the service line covers enzyme induction, enzyme inhibition, reaction phenotyping, and transporter interaction studies. Together, the products and services form an integrated ADME and toxicology solution that uses in vitro systems to closely replicate in vivo drug behavior.
Is ReachBio Research Labs a public or private company?
ReachBio Research Labs is a private company. It is classified as unknown.
When was ReachBio Research Labs founded?
ReachBio Research Labs was founded in 2007. It employs 11 to 50 people.
Where is ReachBio Research Labs based?
ReachBio Research Labs is headquartered in Seattle, United States, in the North America region.
How does ReachBio Research Labs make money?
One revenue line is on record: preclinical ADME-Tox Products.
Who are ReachBio Research Labs's main competitors?
Broad incumbents on record are Eurofins Discovery, Lonza, Corning Life Sciences, Thermo Fisher Scientific and Charles River Laboratories. Direct peers are Cyprotex (Evotec), Sekisui Xenotech and BioIVT. Emerging players are Pharmaron and Inotiv.
Does ReachBio Research Labs have an API?
No public API is recorded for ReachBio Research Labs.
What industry is ReachBio Research Labs in?
ReachBio Research Labs's product category is Preclinical ADME-Tox Reagents and Services. Its primary akta.pro industry code is HLAGAFAC, DMPK / ADME & Bioanalysis, with a secondary code of HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip). Its NAICS code is 541714 and its SIC code is 8731.